About 250 million honeybees loose near U.S.-Canada border after truck overturns
Article content
Article content
The truck hauling an estimated 70,000 pounds (31,751 kilograms) of honeybee hives rolled over around 4 a.m. close to the Canadian border near Lynden, the Whatcom County Sheriff's Office said in social media posts.
Article content
It appears the driver did not navigate a tight turn well enough, causing the trailer to roll into a ditch, county emergency management spokesperson Amy Cloud said in an email. The driver was uninjured, Cloud said.
Article content
Deputies, county public works employees and several bee experts responded to the scene. The box hives later came off the truck, and local beekeepers swarmed to help recover, restore and reset the hives, according to the sheriff's office.
Article content
Article content
250 million bees escape after truck overturns in Washington State yesterday on May 30, 2025. pic.twitter.com/sED6YCiTUm
— non aesthetic things (@PicturesFoIder) May 31, 2025
Article content
The plan is to allow the bees to return to their hives and find their queen bee in the next day or two, according to the sheriff's office. The goal is to save as many of the bees as possible.
Article content
Article content
'Thank you to the wonderful community of beekeepers: over two dozen showed up to help ensure the rescue of millions of pollinating honey bees would be as successful as possible,' the sheriff's office post said.
Article content
The public was advised to avoid the area on Friday, and sheriff's deputies dove into in their squad cars at times to avoid being stung.
Article content
Honeybees are crucial to the food supply, pollinating over 100 crops including nuts, vegetables, berries, citrus and melons. Bees and other pollinators have been declining for years, and experts blame insecticides, parasites, disease, climate change and lack of a diverse food supply.
Article content
In 2018, the U.N. General Assembly sponsored the first 'World Bee Day' on May 20 to bring attention to the bees' plight.
Article content
Beekeepers often transport millions of bees from one location to another because leaving them in one location for too long can deplete resources for other pollinators, The Seattle Times reported.
Article content
Alan Woods, president of the Washington State Beekeepers Association, told the newspaper the state should have a standardized 'emergency bee response' for bee vehicle crashes. In 2015, 14 million bees escaped a truck north of Seattle on Interstate 5 and started stinging people, the newspaper reported at the time.
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Gastrointestinal Stromal Tumor Pipeline strong with 25+ Companies driving therapeutic innovation: DelveInsight
DelveInsight's, 'Gastrointestinal Stromal Tumors Pipeline Insight 2025' report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastrointestinal Stromal Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Gastrointestinal Stromal Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ Gastrointestinal Stromal Tumors Pipeline Outlook Key Takeaways from the Gastrointestinal Stromal Tumors Pipeline Report In June 2025, Merck Sharp & Dohme LLC announced a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). In June 2025, Novartis Pharmaceuticals conducted a study planned a 6-month recruitment phase to enroll 40 subjects, followed by a 6-month treatment phase with monthly visits. Patients benefiting from the treatment could continue during a follow-up phase. In June 2025, Deciphera Pharmaceuticals LLC organized a Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years. DelveInsight's Gastrointestinal Stromal Tumors Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies. The leading Gastrointestinal Stromal Tumors Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others. Promising Gastrointestinal Stromal Tumors Therapies such as Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others. Stay ahead with the most recent pipeline outlook for Gastrointestinal Stromal Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Gastrointestinal Stromal Tumors Approved Drugs Gastrointestinal Stromal Tumors (GIST) Emerging Drugs Famitinib: Jiangsu Hengrui Medicine Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST). Nilotinib: Novartis Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors. THE-630: Theseus Pharmaceuticals THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST). DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy ('payload') to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo's proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors. The Gastrointestinal Stromal Tumors pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumors with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumors Treatment. Gastrointestinal Stromal Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Gastrointestinal Stromal Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumors market. Explore groundbreaking therapies and clinical trials in the Gastrointestinal Stromal Tumors Pipeline. Access DelveInsight's detailed report now! @ Gastrointestinal Stromal Tumors Treatment Drugs Gastrointestinal Stromal Tumors Companies Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others. Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Parenteral Intravenous Subcutaneous Topical Gastrointestinal Stromal Tumors Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Unveil the future of Gastrointestinal Stromal Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Gastrointestinal Stromal Tumors Market Drivers and Barriers Scope of the Gastrointestinal Stromal Tumors Pipeline Report Coverage- Global Gastrointestinal Stromal Tumors Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others. Gastrointestinal Stromal Tumors Therapies- Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others. Gastrointestinal Stromal Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Gastrointestinal Stromal Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Gastrointestinal Stromal Tumors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Gastrointestinal Stromal Tumors Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Gastrointestinal Stromal Tumors: Overview Pipeline Therapeutics Therapeutic Assessment Gastrointestinal Stromal Tumors – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Famitinib: Jiangsu Hengrui Medicine Drug profiles in the detailed report….. Mid Stage Products (Phase II) Nilotinib: Novartis Drug profiles in the detailed report….. Early Stage Products (Phase I) DS 6157: Daiichi Sankyo Company Drug profiles in the detailed report….. Inactive Products Gastrointestinal Stromal Tumors Key Companies Gastrointestinal Stromal Tumors Key Products Gastrointestinal Stromal Tumors- Unmet Needs Gastrointestinal Stromal Tumors- Market Drivers and Barriers Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion Gastrointestinal Stromal Tumors Analyst Views Gastrointestinal Stromal Tumors Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
Attention, Nvidia Shareholders: 1 Crucial Thing to Watch in the Second Half
Key Points Nvidia, after early headwinds, finished the first half of the year with a gain. The company reached a new milestone in recent days, one that could set the tone for share performance in the second half. 10 stocks we like better than Nvidia › The first half was a bit of a roller coaster ride for Nvidia (NASDAQ: NVDA) shareholders. The stock slid almost 30% from the start of the year to early April amid a variety of concerns -- from the future of artificial intelligence (AI) spending to worries that President Trump's import tariffs would weigh on the economy and corporate earnings. Meanwhile, the company continued to launch its new Blackwell platform and delivered double-digit quarterly revenue growth. The message for future prospects is bright too, with Nvidia speaking of soaring demand in the area of AI inference and launching projects abroad such as the building of AI infrastructure in Abu Dhabi. All of this, along with an easing of international trade tensions, prompted investors to return to growth stocks, and one of their top picks has been Nvidia -- the stock finished the first half with a 17% gain. Now, as we head into the second half of the year, you may be wondering how Nvidia will fare -- here's one crucial element to watch. Nvidia's success story Nvidia has built an amazing success story over the years, transforming itself from a company that mainly served the video gaming market to one that's at the center of one of today's highest growth industries. The graphic processing unit (GPU) still is integral to video games, but Nvidia -- thanks to sales of GPUs and related products and services -- today generates most of its revenue from AI customers. For example, in the latest quarter, data center revenue made up 88% of total revenue. This AI giant entered the AI market in its earliest days and aggressively built an empire. Today, selling the world's top-performing GPUs, Nvidia dominates the AI chip market and has pledged to update its chips -- and often complete architecture -- on an annual basis. It launched this annual rhythm with the Blackwell architecture and chip in the fourth quarter of last year -- the rollout went smoothly, Nvidia maintained gross margin in its forecast range, and Blackwell delivered $11 billion in revenue during its first quarter of commercialization. That represented a successful start to this fast-paced innovation plan, and this brings me to the point to watch now -- a new milestone for Nvidia -- as the second half begins. Nvidia's next launch is Blackwell Ultra, and it's already started as cloud player CoreWeave just announced the availability of the platform. CoreWeave now is offering customers access to GB300 NVL72, a system that's a step up from the original Blackwell and a leap from the Hopper architecture -- that was the main Nvidia architecture in use before the original Blackwell launch this winter. GB300 NVL72 may provide a fiftyfold jump in output for reasoning model inference compared to Hopper. A new product launch Now, the point to watch is this Blackwell Ultra rollout, with special attention to demand and whether the process is smooth or not. And once earnings season rolls around, it will be important to look at sales figures as well as gross margin. If this latest update mirrors the Blackwell launch, investors may have something to cheer about -- and we'll have reason to be optimistic about the next chip launches too. Nvidia will have proved its ability to successfully handle frequent chip releases and maintain strong growth and profitability on sales. If there's a glitch along the way or if Nvidia misses a financial goal, then it will be important to dig deeper and examine whether this was just a one-time problem or something that could persist through the next product launches. This is crucial for Nvidia because its market leadership depends on this ability to innovate and successfully roll out a new product. Demand for Blackwell this winter, with it exceeding supply at certain moments, shows us customers are eager to get their hands on the next Nvidia innovation. That's positive, but Nvidia must smoothly deliver on promises in order to keep this momentum going. So far, with the Blackwell launch as a reference point, there's reason to be optimistic. And if Nvidia scores a win with the Blackwell Ultra launch too, the company could see its stock continue to march higher in the second half. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025
Globe and Mail
an hour ago
- Globe and Mail
Crown Castle: A 5.3 Score Amid Management Turmoil
Explore the exciting world of Crown Castle (NYSE: CCI) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jun. 4, 2025. The video was published on Jul. 7, 2025. Should you invest $1,000 in Crown Castle right now? Before you buy stock in Crown Castle, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Crown Castle wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 7, 2025
